Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética

Detalhes bibliográficos
Ano de defesa: 2010
Autor(a) principal: Prigol, Marina
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
dARK ID: ark:/26339/001300000xw9t
Idioma: por
Instituição de defesa: Universidade Federal de Santa Maria
BR
Bioquímica
UFSM
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://repositorio.ufsm.br/handle/1/4418
Resumo: In recent years have been identifical numerous pharmacological properties of a selenium compound, diphenyl diselenide [(PhSe)2]. Consequently, it is important the investigation of its toxic effect for a safe application in pharmacological studies. It is known that babies, in particular, have many physiological and biochemical changes related to development, which increase the susceptibility to toxic effects of drugs. Thus, the article 1 investigated the appearance of seizure episodes induced by (PhSe)2 when administered orally at doses of 5 to 500 mg/kg in rat pups (pos natal day 12-14) and the possible glutamatergic (article 2) and GABAergic (article 3) mechanisms involved in this process. Some studies using different experimental models have demonstrated the most different pharmacological and toxicodynamics properties of (PhSe)2. However, little is known about the toxicokinetic disposition of this compound. Therefore, the aim of article 4 was to determine and quantify the plasma levels of (PhSe)2 in adult mice and rats after oral (p.o.) administration of 500 mg/kg (PhSe)2; to verify the involvement of different routes of administration, vehicle and animal species in plasma levels of (PhSe)2 and in the onset of the first seizure episode induced by it. In article 5, it was determined and quantified the levels of (PhSe)2 in plasma, liver and brain of rat pups and these levels were correlated to the latency for the onset of the first seizure episode. To obtain more information about the compound, which were to supplement the data obtained, we carried out in vitro kinetic models. The manuscript 1 investigated the drug-like properties of (PhSe)2 in regards to stability, solubility, absorption and plasma protein binding (PPB) in vitro. In manuscript 2, it was conducted an in vitro study in order to identify possible metabolic pathways responsible for the biotransformation of (PhSe)2 in the body. Results of article 1 showed that administration of (PhSe)2 caused toxicity in rat pups, evidenced by the appearance of seizures. These were dose dependent and were, at least in part, related to oxidative stress. Among the mechanisms involved in the convulsive effect of (PhSe)2 were the interaction with: glutamatergic system by stimulating the inotropic glutamatergic receptors NMDA and by inhibiting the uptake of glutamate (Article 2); GABAergic system by antagonize the GABAA receptor, stimulating GABA transaminase enzyme and increasing GABA uptake (Article 3). The article 4 revealed that the maximum concentration of (PhSe)2 in the plasma of adult rats and mice occurred 30 minutes after p.o administration of the compound and remained detectable up to 8 hours after administration. The use of different routes of administration (intraperitoneal (i.p.), p.o., subcutaneous (s.c.)) or vehicle (canola oil or dimethyl sulfoxide (DMSO)) in rats and mice indicated that the onset of the first seizure episode and plasma levels are dependent on the route of administration (i.p. > p.o. > s.c.), vehicle (DMSO > canola oil) and animal species (mouse > rat). In article 5, it was observed that rat pups showed seizures even presenting lower plasma values of (PhSe)2 as compared to adults. This result demonstrated that rat pups are more sensitive to the toxic effects of (PhSe)2 than adult rats. Levels of (PhSe)2 in the liver and brain of rat pups showed a negative correlation with the latency to the first seizure episode. The manuscript 1 showed that (PhSe)2 has chemical and biological stability. However, the compound has a low solubility in water, a high partition coefficient octanol-water and an extensive plasma protein binding. Manuscript 2 indicated that (PhSe)2 is not biotranformed by Phase I reactions, catalyzed by cytochrome P450. It reacted chemically with reduced glutathione (GSH) and N-acetylcysteine (NAC) to form adducts or reacts with protein SH groups. The presence of GSH or NAC in the incubation medium decreased the binding of (PhSe)2 protein. Finally, it was observed that (PhSe)2 reduced the activity of cytochrome P450. Together, the data presented showed that the intensity of toxic effects caused by (PhSe)2 are directly related to its toxicokinetic.
id UFSM_a655c262bc9ac72a9981951a200d428d
oai_identifier_str oai:repositorio.ufsm.br:1/4418
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinéticaConvulsive action of diphenyl diselenide in rats: study of the neurochemistry mechanisms and toxicokineticDisseleneto de difenilaSelênioConvulsãoRatos bebêNeuroquímicaToxicocinéticaMetabolismoDiphenyl diselenideSeleniumSeizuresRat pupsNeurochemistryToxicokineticMetabolismCNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICAIn recent years have been identifical numerous pharmacological properties of a selenium compound, diphenyl diselenide [(PhSe)2]. Consequently, it is important the investigation of its toxic effect for a safe application in pharmacological studies. It is known that babies, in particular, have many physiological and biochemical changes related to development, which increase the susceptibility to toxic effects of drugs. Thus, the article 1 investigated the appearance of seizure episodes induced by (PhSe)2 when administered orally at doses of 5 to 500 mg/kg in rat pups (pos natal day 12-14) and the possible glutamatergic (article 2) and GABAergic (article 3) mechanisms involved in this process. Some studies using different experimental models have demonstrated the most different pharmacological and toxicodynamics properties of (PhSe)2. However, little is known about the toxicokinetic disposition of this compound. Therefore, the aim of article 4 was to determine and quantify the plasma levels of (PhSe)2 in adult mice and rats after oral (p.o.) administration of 500 mg/kg (PhSe)2; to verify the involvement of different routes of administration, vehicle and animal species in plasma levels of (PhSe)2 and in the onset of the first seizure episode induced by it. In article 5, it was determined and quantified the levels of (PhSe)2 in plasma, liver and brain of rat pups and these levels were correlated to the latency for the onset of the first seizure episode. To obtain more information about the compound, which were to supplement the data obtained, we carried out in vitro kinetic models. The manuscript 1 investigated the drug-like properties of (PhSe)2 in regards to stability, solubility, absorption and plasma protein binding (PPB) in vitro. In manuscript 2, it was conducted an in vitro study in order to identify possible metabolic pathways responsible for the biotransformation of (PhSe)2 in the body. Results of article 1 showed that administration of (PhSe)2 caused toxicity in rat pups, evidenced by the appearance of seizures. These were dose dependent and were, at least in part, related to oxidative stress. Among the mechanisms involved in the convulsive effect of (PhSe)2 were the interaction with: glutamatergic system by stimulating the inotropic glutamatergic receptors NMDA and by inhibiting the uptake of glutamate (Article 2); GABAergic system by antagonize the GABAA receptor, stimulating GABA transaminase enzyme and increasing GABA uptake (Article 3). The article 4 revealed that the maximum concentration of (PhSe)2 in the plasma of adult rats and mice occurred 30 minutes after p.o administration of the compound and remained detectable up to 8 hours after administration. The use of different routes of administration (intraperitoneal (i.p.), p.o., subcutaneous (s.c.)) or vehicle (canola oil or dimethyl sulfoxide (DMSO)) in rats and mice indicated that the onset of the first seizure episode and plasma levels are dependent on the route of administration (i.p. > p.o. > s.c.), vehicle (DMSO > canola oil) and animal species (mouse > rat). In article 5, it was observed that rat pups showed seizures even presenting lower plasma values of (PhSe)2 as compared to adults. This result demonstrated that rat pups are more sensitive to the toxic effects of (PhSe)2 than adult rats. Levels of (PhSe)2 in the liver and brain of rat pups showed a negative correlation with the latency to the first seizure episode. The manuscript 1 showed that (PhSe)2 has chemical and biological stability. However, the compound has a low solubility in water, a high partition coefficient octanol-water and an extensive plasma protein binding. Manuscript 2 indicated that (PhSe)2 is not biotranformed by Phase I reactions, catalyzed by cytochrome P450. It reacted chemically with reduced glutathione (GSH) and N-acetylcysteine (NAC) to form adducts or reacts with protein SH groups. The presence of GSH or NAC in the incubation medium decreased the binding of (PhSe)2 protein. Finally, it was observed that (PhSe)2 reduced the activity of cytochrome P450. Together, the data presented showed that the intensity of toxic effects caused by (PhSe)2 are directly related to its toxicokinetic.Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorNos últimos anos, têm sido identificadas inúmeras propriedades farmacológicas do composto de selênio disseleneto de difenila [(PhSe)2]. Assim, a pesquisa dos efeitos tóxicos deste composto torna-se importante para a segurança na aplicação farmacológica. Sabe-se que os bebês, em particular, apresentam muitas mudanças fisiológicas e bioquímicas relacionadas ao desenvolvimento, que aumentam a suscetibilidade aos efeitos tóxicos de drogas. Desta forma, no artigo 1 investigou-se o aparecimento de convulsões induzida pelo (PhSe)2, quando administrado pela via oral (p.o), nas doses de 5 à 500 mg/kg em ratos bebês (12-14 dias de vida) bem como os possíveis mecanismos glutamatérgicos (Artigo 2) e GABAérgicos (Artigo 3) envolvidos em tal processo. Vários estudos, utilizando diferentes modelos experimentais demonstraram as mais diferentes propriedades farmacológicas e toxicodinâmicas do (PhSe)2 no entanto, pouco se conhece sobre a toxicodinâmica deste composto. Por isso, o objetivo do artigo 4 foi determinar e quantificar os níveis plasmáticos de (PhSe)2 em ratos e camundongos adultos após a administração p.o. de (PhSe)2 na dose de 500 mg/kg; bem como verificar o envolvimento de diferentes vias de administração, veículos e espécie animal nos níveis plasmáticos do composto e no aparecimento de convulsões induzidas pelo mesmo. No artigo 5, determinou-se e quantificou-se os níveis de (PhSe)2 no plasma, fígado e cérebro de ratos bebês e correlacionou-se estes níveis à latência para o aparecimento de convulsões. Devido a necessidade de obter mais informações sobre o composto, que viessem a complementar os dados obtidos, realizou-se modelos cinéticos in vitro. O manuscrito 1 investigou parâmetros relacionados a estabilidade, solubilidade, absorção e ligação às proteínas plasmáticas do (PhSe)2 in vitro. No manuscrito 2 realizou-se um estudo in vitro para identificar as vias metabólicas responsáveis pela biotransformação do (PhSe)2 no organismo. Os resultados do artigo 1 demonstraram que a administração de (PhSe)2 causou toxicidade em ratos bebês, evidenciada pelo aparecimento de convulsões. Estas são dependentes da dose utilizada e estão, pelo menos em parte, relacionadas ao estresse oxidativo. Dentre os mecanismos neuroquímicos envolvidos no efeito convulsivante do (PhSe)2 estão a interação com o sistema glutamatérgico, por estimular os receptores glutamatérgicos ionotrópicos do tipo NMDA e por inibir a captação de glutamato (Artigo 2); e com o sistema GABAérgico, por antagonizar os receptores GABAégicos do tipo GABAA, estimulando a enzima GABA transaminase e estimulando a captação de GABA (Artigo 3). O artigo 4 demonstrou que concentração máxima de (PhSe)2 no plasma de ratos e camundongos adultos ocorreu 30 minutos após a administração pela via oral do composto e permaneceu detectável até 8 horas após sua administração. O uso de diferentes vias de administração (intraperitonial (i.p); p.o; subcutânea (s.c)) e veículo (óleo de canola ou dimetil sulfóxido (DMSO)) em ratos e camundongos indicou que o aparecimento de convulsões e os níveis plasmáticos de (PhSe)2 são dependentes da via de administração (i.p > p.o > s.c), do veículo (DMSO > óleo de canola) e da espécie animal (camundongo > rato). No artigo 5 observou-se ainda que os ratos bebês convulsionaram mesmo apresentando níveis plasmáticos menores de composto que os adultos, o que nos leva a crer que estes são mais sensíveis aos feitos tóxicos do (PhSe)2. Os níveis de (PhSe)2 no fígado e no cérebro de ratos bebês no momento do episódio convulsivo apresentaram uma correlação negativa com a latência para o primeiro episódio convulsivo. O manuscrito 1 revelou que o (PhSe)2 apresenta estabilidade química e biológica. No entanto, o composto apresenta uma baixa solubilidade em água, um alto coeficiente de partição octanol-água e uma extensa ligação às proteínas plasmáticas. O manuscrito 2 indicou que o (PhSe)2 não é biotransformado por reações de fase I catalizadas pelo citocromo P450. O composto reage quimicamente com a glutationa reduzida (GSH) e a N-acetilciateína (NAC), formando adutos ou ainda reage com grupos SH de proteínas. A presença de GSH ou NAC no meio de incubação diminuiu a ligação do (PhSe)2 às proteínas. Por fim, foi observado que o (PhSe)2 reduziu a atividade das enzimas do citocromo P450. Em conjunto, os resultados desta tese demonstraram que a intensidade dos efeitos tóxicos causados pelo (PhSe)2 estão diretamente relacionados a sua toxicocinética.Universidade Federal de Santa MariaBRBioquímicaUFSMPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica ToxicológicaZeni, Gilson Rogériohttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4728651J6Garcia, Solange Cristinahttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4790220Y7Royes, Luiz Fernando Freirehttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4705849Y0Furian, Ana Fláviahttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4705849T6Meotti, Flavia Carlahttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4705185D2Prigol, Marina2017-04-252017-04-252010-07-27info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisapplication/pdfapplication/pdfPRIGOL, Marina. Convulsive action of diphenyl diselenide in rats: study of the neurochemistry mechanisms and toxicokinetic. 2010. 190 f. Tese (Doutorado em Bioquímica) - Universidade Federal de Santa Maria, Santa Maria, 2010.http://repositorio.ufsm.br/handle/1/4418ark:/26339/001300000xw9tporinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2017-07-25T14:06:33Zoai:repositorio.ufsm.br:1/4418Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/PUBhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.bropendoar:2017-07-25T14:06:33Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
Convulsive action of diphenyl diselenide in rats: study of the neurochemistry mechanisms and toxicokinetic
title Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
spellingShingle Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
Prigol, Marina
Disseleneto de difenila
Selênio
Convulsão
Ratos bebê
Neuroquímica
Toxicocinética
Metabolismo
Diphenyl diselenide
Selenium
Seizures
Rat pups
Neurochemistry
Toxicokinetic
Metabolism
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA
title_short Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
title_full Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
title_fullStr Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
title_full_unstemmed Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
title_sort Ação convulsivante do disseleneto de difenila em ratos: estudo dos mecanismos neuroquímicos e da toxicocinética
author Prigol, Marina
author_facet Prigol, Marina
author_role author
dc.contributor.none.fl_str_mv Zeni, Gilson Rogério
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4728651J6
Garcia, Solange Cristina
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4790220Y7
Royes, Luiz Fernando Freire
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4705849Y0
Furian, Ana Flávia
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4705849T6
Meotti, Flavia Carla
http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4705185D2
dc.contributor.author.fl_str_mv Prigol, Marina
dc.subject.por.fl_str_mv Disseleneto de difenila
Selênio
Convulsão
Ratos bebê
Neuroquímica
Toxicocinética
Metabolismo
Diphenyl diselenide
Selenium
Seizures
Rat pups
Neurochemistry
Toxicokinetic
Metabolism
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA
topic Disseleneto de difenila
Selênio
Convulsão
Ratos bebê
Neuroquímica
Toxicocinética
Metabolismo
Diphenyl diselenide
Selenium
Seizures
Rat pups
Neurochemistry
Toxicokinetic
Metabolism
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA
description In recent years have been identifical numerous pharmacological properties of a selenium compound, diphenyl diselenide [(PhSe)2]. Consequently, it is important the investigation of its toxic effect for a safe application in pharmacological studies. It is known that babies, in particular, have many physiological and biochemical changes related to development, which increase the susceptibility to toxic effects of drugs. Thus, the article 1 investigated the appearance of seizure episodes induced by (PhSe)2 when administered orally at doses of 5 to 500 mg/kg in rat pups (pos natal day 12-14) and the possible glutamatergic (article 2) and GABAergic (article 3) mechanisms involved in this process. Some studies using different experimental models have demonstrated the most different pharmacological and toxicodynamics properties of (PhSe)2. However, little is known about the toxicokinetic disposition of this compound. Therefore, the aim of article 4 was to determine and quantify the plasma levels of (PhSe)2 in adult mice and rats after oral (p.o.) administration of 500 mg/kg (PhSe)2; to verify the involvement of different routes of administration, vehicle and animal species in plasma levels of (PhSe)2 and in the onset of the first seizure episode induced by it. In article 5, it was determined and quantified the levels of (PhSe)2 in plasma, liver and brain of rat pups and these levels were correlated to the latency for the onset of the first seizure episode. To obtain more information about the compound, which were to supplement the data obtained, we carried out in vitro kinetic models. The manuscript 1 investigated the drug-like properties of (PhSe)2 in regards to stability, solubility, absorption and plasma protein binding (PPB) in vitro. In manuscript 2, it was conducted an in vitro study in order to identify possible metabolic pathways responsible for the biotransformation of (PhSe)2 in the body. Results of article 1 showed that administration of (PhSe)2 caused toxicity in rat pups, evidenced by the appearance of seizures. These were dose dependent and were, at least in part, related to oxidative stress. Among the mechanisms involved in the convulsive effect of (PhSe)2 were the interaction with: glutamatergic system by stimulating the inotropic glutamatergic receptors NMDA and by inhibiting the uptake of glutamate (Article 2); GABAergic system by antagonize the GABAA receptor, stimulating GABA transaminase enzyme and increasing GABA uptake (Article 3). The article 4 revealed that the maximum concentration of (PhSe)2 in the plasma of adult rats and mice occurred 30 minutes after p.o administration of the compound and remained detectable up to 8 hours after administration. The use of different routes of administration (intraperitoneal (i.p.), p.o., subcutaneous (s.c.)) or vehicle (canola oil or dimethyl sulfoxide (DMSO)) in rats and mice indicated that the onset of the first seizure episode and plasma levels are dependent on the route of administration (i.p. > p.o. > s.c.), vehicle (DMSO > canola oil) and animal species (mouse > rat). In article 5, it was observed that rat pups showed seizures even presenting lower plasma values of (PhSe)2 as compared to adults. This result demonstrated that rat pups are more sensitive to the toxic effects of (PhSe)2 than adult rats. Levels of (PhSe)2 in the liver and brain of rat pups showed a negative correlation with the latency to the first seizure episode. The manuscript 1 showed that (PhSe)2 has chemical and biological stability. However, the compound has a low solubility in water, a high partition coefficient octanol-water and an extensive plasma protein binding. Manuscript 2 indicated that (PhSe)2 is not biotranformed by Phase I reactions, catalyzed by cytochrome P450. It reacted chemically with reduced glutathione (GSH) and N-acetylcysteine (NAC) to form adducts or reacts with protein SH groups. The presence of GSH or NAC in the incubation medium decreased the binding of (PhSe)2 protein. Finally, it was observed that (PhSe)2 reduced the activity of cytochrome P450. Together, the data presented showed that the intensity of toxic effects caused by (PhSe)2 are directly related to its toxicokinetic.
publishDate 2010
dc.date.none.fl_str_mv 2010-07-27
2017-04-25
2017-04-25
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv PRIGOL, Marina. Convulsive action of diphenyl diselenide in rats: study of the neurochemistry mechanisms and toxicokinetic. 2010. 190 f. Tese (Doutorado em Bioquímica) - Universidade Federal de Santa Maria, Santa Maria, 2010.
http://repositorio.ufsm.br/handle/1/4418
dc.identifier.dark.fl_str_mv ark:/26339/001300000xw9t
identifier_str_mv PRIGOL, Marina. Convulsive action of diphenyl diselenide in rats: study of the neurochemistry mechanisms and toxicokinetic. 2010. 190 f. Tese (Doutorado em Bioquímica) - Universidade Federal de Santa Maria, Santa Maria, 2010.
ark:/26339/001300000xw9t
url http://repositorio.ufsm.br/handle/1/4418
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Bioquímica
UFSM
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Bioquímica
UFSM
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.br
_version_ 1847153300859781120